HR-positive/HER2-negative breast cancer grows with estrogen or progesterone, lacking high HER2 protein levels, making hormone ...

Normally, HER2 helps your healthy breast cells grow and divide. But too much HER2 can trigger cells to grow out of control. HER2-positive breast cancer happens when the HER2 gene in your DNA mutates ...

The addition of neoadjuvant trastuzumab deruxtecan (T-DXd; Enhertu) significantly improved pathologic complete response (pCR) ...

The FDA approved pertuzumab-dpzb (Poherdy) as the first biosimilar for its reference product Perjeta, a monoclonal antibody ...

A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast ...

The U.S. Food and Drug Administration (FDA) approved Poherdy (pertuzumab-dpzb) as the first interchangeable biosimilar to ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Miller: Before we ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Now, if ever there ...

EirGenix Inc. (TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the ...

If you or a loved one has lung cancer, you may be looking into treatment options. A new medicine you might hear about is Hernexeos (zongertinib). More specifically, Hernexeos is FDA-approved to treat ...

Boehringer recently reported positive results from the Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced NSCLC at ESMO 2025. The company is pursuing regulatory ...